Crispr Therapeutics stock has undergone multiple analysts rating changes in the recent past.  Crispr Therapeutics stock Target Raised by   Canaccord Genuity on 6/15/2020. In a note to investors, the firm issued a new target price of $84.00. The analysts previously had $80.00 target price. Canaccord Genuity’s price target would indicate a potential upside of 40.26% from the stock’s previous close.

Shares of Crispr Therapeutics traded up $2.48 on Monday, reaching $62.37. 305039 shares of the stock traded hands, compared to its average volume of 974914. Shares of CRSP
Crispr Therapeutics were trading at $62.37 on Monday. The firm’s 50 day moving average is $$56.30 and its 200 day moving average is $53.04.Crispr Therapeutics  has a 12 month low of $59.19 and a 12 month high of $74.00. While on yearly highs and lows, Crispr Therapeutics today has traded high as $62.48 and has touched $59.19 on the downward trend.

Crispr Therapeutics Earnings and What to expect: 

Crispr Therapeutics last posted its quarterly earnings data on April 28th, 2020. The reported ($1.15) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.05) by $0.10. The firm had revenue of $0.16 million for the quarter, compared to the consensus estimate of $3.04 million. Its quarterly revenue was down 52.1% on a year-over-year basis. Crispr Therapeutics has generated $1.17 earnings per share over the last year and currently has a price-to-earnings ratio of 80.4. Crispr Therapeutics has not formally confirmed its next earnings publication date, but the company’s estimated earnings date is Monday, August 3rd, 2020 based off prior year’s report dates.

Earnings for Crispr Therapeutics are expected to decrease in the coming year, from ($4.51) to ($5.22) per share. The P/E ratio of Crispr Therapeutics is 80.44, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 15.72. The P/E ratio of Crispr Therapeutics is 80.44, which means that it is trading at a more expensive P/E ratio than the Medical sector average P/E ratio of about 27.42. Crispr Therapeutics has a P/B Ratio of 3.54. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Latest Insiders Trading and Volume : 

  • Insider Ownership Percentage: 17.10%
  • On 6/1/2020 CEO Samarth Kulkarni Sell 17,275 at average share price of $64.68 which equates to $1,117,347.00 in money value.
  • On 5/20/2020 CEO Samarth Kulkarni Sell 10,693 at average price of  $65.28 with total value of : Not Data Available
  • On 5/19/2020 President Rodger Novak Sell 50,000 at average price of  $65.00 with total value of : $3,250,000.00
  • See More Analyst Rating at: RATING

Other Analyst’s rating for Crispr Therapeutics

  • 6/12/2020 – Crispr Therapeutics had its “buy” rating re-affirmed by analysts at Piper Sandler. They now have a $104.00 price target on the stock.
  • 6/12/2020 – Crispr Therapeutics had its “buy” rating re-affirmed by analysts at Chardan Capital. They now have a $72.50 price target on the stock.
  • 6/12/2020 – Crispr Therapeutics is now covered by analysts at Needham & Company LLC. They set a “buy” rating and a $84.00 price target on the stock.
  • 6/12/2020 – Crispr Therapeutics is now covered by analysts at Oppenheimer Holdings Inc.. They set a “buy” rating and a $80.00 price target on the stock.
  • See More Analyst Rating at: RATING

Other rating updates by Canaccord Genuity: 

  • 6/15/2020 – Welltower was upgraded by analysts at Canaccord Genuity to a “speculative buy” rating. They now have a $3.25 price target on the stock.
  • 6/15/2020 – Consolidated Graphics had its price target lowered by analysts at Canaccord Genuity from $21.50 to $17.00. They now have a “speculative buy” rating on the stock.
  • 6/15/2020 – Cineplex had its “buy” rating re-affirmed by analysts at Canaccord Genuity. They now have a $17.00 price target on the stock.
  • 6/15/2020 – Spectra7 Microsystems had its “sell” rating re-affirmed by analysts at Canaccord Genuity. They now have a $0.01 price target on the stock.
  • See More Analyst Rating at: RATING

Crispr Therapeutics (NASDAQ:CRSP) Moving Average Technical Analysis

5 day Moving Average is $$61.13 And 5 day price change is -$0.74 (-1.22%)  with average volume for 5 day average is 717,915. While technical analysis for average 20 days shows significant difference, 20 day moving average is  $64.06 and 20 day price change is -$1.30 (-2.13%) and average 20 day moving volume is 899,559. 50 day moving average is $56.30  and 50 day price change is $20.28 ( 51.33%)  and with average volume for 50 days is : 900,805. 200 day moving average is $53.04  and 200 day price change is $13.70 (29.72%)  and with average volume for 200 days is : 944,805.

See More Analyst Rating at: RATING



Source link